On March 17, 2026 GV20 Therapeutics (GV20), a clinical-stage AI-powered biotherapeutics company, reported that it has been selected to deliver a late-breaking oral presentation highlighting translational data of GV20-0251 at the American Association of Cancer Research 2026 Annual Meeting, taking place in San Diego on April 17- 22, 2026.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
This presentation at AACR (Free AACR Whitepaper) builds on previously presented clinical data of the novel immune checkpoint IGSF8 inhibitor GV20-0251 (Wentzel et al, ASCO (Free ASCO Whitepaper) 2025) and will report the translational findings, including pharmacodynamic and potential predictive biomarkers data, from the monotherapy dose escalation portion of the ongoing Phase 1/2 trial evaluating GV20-0251 in patients with advanced solid tumors resistant to anti-PD(L)1 and other standard therapies (NCT05669430).
Presentation details (Abstract CT001):
Title: Evaluation of pharmacodynamic and potential predictive biomarkers for GV20-0251, an anti-IGSF8 antibody, as monotherapy from ongoing Phase 1/2a study
Session Title: Updates in Anticancer Immunotherapies
Session Type: Oral Clinical Trial Minisymposium
Session Date/Time: Saturday April 18, 2026, 10:00 AM – 12:00 PM PDT
(Press release, GV20 Therapeutics, MAR 17, 2026, View Source [SID1234663638])